Onychomycosis Market Size in the US was ~USD 760 million in 2023, is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Oncychomycosis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Oncychomycosis, historical and forecasted epidemiology as well as the Oncychomycosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Oncychomycosis Market with DelveInsight's In-Depth Report @ Oncychomycosis Market Size [https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Oncychomycosis Market Report

* The total prevalent cases of Onychomycosis in the US was found to be 37,250 thousand in the year 2023. These cases are expected to change significantly by 2034.
* In 2023, when prevalent cases of onychomycosis were segmented based on severity in Germany, moderate cases stood out as the highest, totaling about 726 thousand. These figures are expected to fluctuate during the forecast period from 2024 to 2034.
* In the UK, when Onychomycosis cases were categorized by Subtype, a notable disparity was observed, with a higher prevalence of distal subungual onychomycosis compared to superficial white onychomycosis, proximal subungual onychomycosis, and Candidal onychomycosis. In 2023, approximately 861 thousand cases of Onychomycosis were recorded in the distal subungual onychomycosis, and these figures are expected to undergo further fluctuations throughout the study period spanning from 2020 to 2034.
* In 2023, France had around 11,465 thousand prevalent cases of Onychomycosis. These cases are expected to further change by 2034.
* In 2023, Japan recorded approximately 2,296 thousand diagnosed prevalent cases of Onychomycosis. It is anticipated that these figures will undergo further fluctuations by the year 2034.
* In Japan, moderate onychomycosis emerged as the dominant severity category, comprising approximately 916 thousand cases in 2023, followed by severe cases. Mild onychomycosis represented the lowest proportion of cases.
* The leading Oncychomycosis Companies such as Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others.
* Promising Oncychomycosis Therapies such as KERYDIN (tavaborole), JUBLIA/CLENAFIN (efinaconazole), BB2603, VT-1161, and others

Stay ahead in the Oncychomycosis Therapeutics Market with DelveInsight's Strategic Report @ Oncychomycosis Market Outlook [https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Oncychomycosis Epidemiology Segmentation in the 7MM

* Total Prevalent cases of Onychomycosis
* Total diagnosed Prevalent cases of Onychomycosis
* Subtype-specific diagnosed prevalent cases of Onychomycosis
* Severity-specific diagnosed prevalent cases of Onychomycosis

Download the report to understand which factors are driving Oncychomycosis Epidemiology trends @ Oncychomycosis Prevalence [https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Onychomycosis Marketed Therapies

* KERYDIN (tavaborole): Pfizer

KERYDIN (tavaborole) topical solution, contains tavaborole, 5% (w/w) in a clear, colorless alcohol-based solution for topical use. The active ingredient, tavaborole, is an oxaborole antifungal. Tavaborole is a white to off-white powder and is slightly soluble in water and freely soluble in ethanol and propylene glycol. Kerydrin contains 43.5 mg of tavaborole/mL of solution. Inactive ingredients include alcohol, edetate calcium disodium, and propylene glycol.

* JUBLIA/CLENAFIN (efinaconazole): Bausch Health

Efinaconazole 10% nail solution (JUBLIA) is a new topical triazole antifungal designed for the topical treatment of distal and lateral subungual onychomycosis. Efinaconazole has lower minimum inhibitory concentrations than terbinafine, ciclopirox, itraconazole, and amorolfine in Trichophyton rubrum, Trichophyton mentagrophytes, and Candida albicans. The solution-based formula has low surface tension and keratin binding properties that increase penetrance through the nail plate. Safety studies have shown that this formulation is not associated with atopic dermatitis or contact sensitivity. Efinaconazole 10% nail solution is a safe and effective new topical therapy for onychomycosis, which will fill a pressing need for more effective topical therapy in this disease. It is marketed under the brand name JUBLIA in the US and CLENAFIN in Japan.

Emerging Therapies for Onychomycosis

* BB2603: Blueberry Therapeutics

Blueberry Therapeutics' BB2603 is squalene epoxidase inhibitor BB2603 in a spray formulation is currently ongoing Phase I/II trials to treat onychomycosis and its associated tinea pedis. BB2603 is an innovative new treatment concept using nanotechnology to deliver terbinafine, a potent antifungal, through the nail and into the skin to treat fungal infection.

* VT-1161: Mycovia Pharmaceuticals

VT-1161 is a potent and selective, orally available inhibitor of fungal CYP51. In in vitro and in vivo studies, VT-1161 has demonstrated broad-spectrum activity against Candida species, a broad family of fungi that resemble yeasts and frequently cause infections in humans, and dermatophytes, a broad family of fungi that frequently cause skin, nail, and hair infections. Based on their research to date, the company believes that VT-1161 is highly active against most species of Candida. In addition, the drug is highly active against Trichophyton rubrum and Trichophyton mentagrophytes - the two most common dermatophyte species that cause onychomycosis. As VT-1161 is highly selective for fungal CYP51, it is believed that it may avoid the side effects that limit the use of commonly prescribed antifungals, including fluconazole, itraconazole, posaconazole, terbinafine, and voriconazole.

To learn more about Oncychomycosis treatment guidelines, visit @ Oncychomycosis Treatment Market Landscape [https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Onychomycosis Market Outlook

Onychomycosis is primarily a fungal infection of the nail bed. It is commonly referred to as 'toenail fungus' because toenail infections constitute the majority of onychomycosis cases. Toenail disorders are one of the most prevalent foot complaints for which adults seek over-the-counter treatments and professional care. The infection typically begins as a small white or yellow spot beneath the nail plate, causing nail discoloration and thickening and splitting of the nail. It is estimated that the disease affects nearly 3% of the general adult population with around ~20% of the individuals between the ages of 40 and 60 years being affected.

Scope of the Oncychomycosis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Oncychomycosis Companies- Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, and others.
* Oncychomycosis Therapies- KERYDIN (tavaborole), JUBLIA/CLENAFIN (efinaconazole), BB2603, VT-1161, and others.
* Oncychomycosis Market Dynamics: Oncychomycosis Market Drivers and Barriers
* Oncychomycosis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Oncychomycosis Drugs in development @ Oncychomycosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Onychomycosis Market Overview at a Glance

4 Executive Summary of Onychomycosis

5 Disease Background and Overview

6 Treatment of Onychomycosis

7 Management of Onychomycosis

8 Guidelines

8.1 British Association of Dermatologists' (BAD) guidelines for the management of onychomycosis

9 Epidemiology and Patient Population

10 Patient Journey

11 Marketed Products

12 Emerging Therapies

13 Onychomycosis: Seven Major Market

14 Key Opinion Leaders' Views

15 SWOT Analysis

16 Unmet Needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=onychomycosis-market-size-in-the-us-was-usd-760-million-in-2023-is-expected-to-grow-at-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.